Gossamer Bio Inc (NASDAQ:GOSS) Short Interest Up 15.5% in May

Share on StockTwits

Gossamer Bio Inc (NASDAQ:GOSS) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 1,577,200 shares, a growth of 15.5% from the April 30th total of 1,365,000 shares. Approximately 6.3% of the company’s shares are short sold. Based on an average daily volume of 173,700 shares, the short-interest ratio is currently 9.1 days.

NASDAQ GOSS traded up $1.01 on Wednesday, hitting $22.32. 188,800 shares of the stock were exchanged, compared to its average volume of 248,587. The company has a quick ratio of 19.79, a current ratio of 19.79 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -0.99. Gossamer Bio has a 52-week low of $15.59 and a 52-week high of $25.06.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.27). Equities research analysts anticipate that Gossamer Bio will post -2.61 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of GOSS. Omega Fund Management LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at about $150,681,000. FMR LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at about $26,576,000. Victory Capital Management Inc. bought a new stake in shares of Gossamer Bio in the first quarter valued at about $18,649,000. Federated Investors Inc. PA bought a new stake in shares of Gossamer Bio in the first quarter valued at about $15,992,000. Finally, Marshall Wace North America L.P. bought a new stake in shares of Gossamer Bio in the first quarter valued at about $9,523,000. 52.76% of the stock is owned by hedge funds and other institutional investors.

GOSS has been the subject of several research reports. Zacks Investment Research upgraded shares of Gossamer Bio from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Tuesday, May 28th. Svb Leerink began coverage on shares of Gossamer Bio in a research report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price objective on the stock. Barclays began coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “overweight” rating and a $27.00 price target on the stock. Evercore ISI initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 price target on the stock. Finally, Bank of America initiated coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Gossamer Bio has an average rating of “Buy” and an average target price of $28.00.

ILLEGAL ACTIVITY NOTICE: “Gossamer Bio Inc (NASDAQ:GOSS) Short Interest Up 15.5% in May” was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4380296/gossamer-bio-inc-nasdaqgoss-short-interest-up-15-5-in-may.html.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: The role of implied volatility with call option volume

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sensient Technologies  to Release Earnings on Friday
Sensient Technologies to Release Earnings on Friday
Zacks Investment Research Downgrades Aurora Cannabis  to Sell
Zacks Investment Research Downgrades Aurora Cannabis to Sell
Abbott Laboratories  Given New $93.00 Price Target at Morgan Stanley
Abbott Laboratories Given New $93.00 Price Target at Morgan Stanley
ValuEngine Downgrades AMBEV S A/S  to Hold
ValuEngine Downgrades AMBEV S A/S to Hold
Aaron’s  Price Target Raised to $70.00
Aaron’s Price Target Raised to $70.00
Alcoa  Stock Rating Upgraded by ValuEngine
Alcoa Stock Rating Upgraded by ValuEngine


© 2006-2019 Ticker Report